Alvotech (ALVO) Jumped, So What Is Behind The Latest Move?

Alvotech (NasdaqGM:ALVO) is back on investors’ radar after a recent 7% daily gain and a mid single digit move over the past week, which contrasts with a decline over the past month.

At a share price of US$4.86, Alvotech’s recent 6.8% 1 day share price return and 4.5% 7 day share price return come after a 16.9% share price decline over 30 days, while the 1 year total shareholder return is down 14.9% despite a 27.6% 90 day share price gain.

Scan the wider biosimilar and healthcare space by comparing Alvotech’s recent swings with a hand picked group of 35 healthcare AI stocks.

Alvotech now trades well below analyst targets and a modeled estimate of fair value, even after the latest rebound. Is that discount compensation for real risks or caution that has gone too far?

Most Popular Narrative: 32% Undervalued

Alvotech is priced at $4.86, while the most followed narrative anchors fair value at $7.20. The story hinges on whether execution and financing catch up with that gap.

Alvotech’s current valuation implies the market places limited value on guidance for 2026 revenue of US$650 to US$700 million with adjusted EBITDA of US$180 to US$220 million, the push toward higher long-term EBITDA margins and the potential for a richer mix of first-wave biosimilars.

See why 14 investors see Alvotech as 32% undervalued.

Result: Fair Value of $7.20 (UNDERVALUED)

Still, the narrative around Alvotech only holds if execution improves, since recent revenue decline and higher cost debt could continue to pressure earnings and cash.

Find out about the key risks to this Alvotech narrative.

Next Steps

Signals on Alvotech appear mixed so far, and it may not be clear where you stand on it. Consider acting while sentiment remains divided and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Alvotech?

If Alvotech has your attention, do not stop there. Use the Simply Wall Street Screener to surface fresh ideas that match the way you like to invest.

• Target potential mispricings by scanning companies that combine quality fundamentals with appealing valuations through the 39 high quality undervalued stocks.
• Build a steadier income stream by hunting for resilient payers using the 8 dividend fortresses.
• Cut portfolio risk by filtering for financially robust businesses with the list of solid balance sheet and fundamentals (24 results).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com